Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 280 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... November 21, 2020 Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... February 8, 2024 Can Eating Grilled or Charred Foods Cause Cancer? January 10, 2023 Black In Cancer – That Cancer Conversation October 8, 2021 Load more HOT NEWS Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... Time to get stratified What to Expect During a Skin Cancer Screening Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs
